Clinical Trial

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Study acronym: PIOHF
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-20; most recent amendment 2025-08-26.
Status change: Not Yet Recruiting → Recruiting 2023-07-13
Trial Details
NCT Number NCT05838287
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Enrollment 78 participants
Start Date 2023-07-10
Primary Completion 2029-08 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-27